Palivizumab( —— )

Catalog No. M36768 CAS No. 188039-54-5

Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	347	Get Quote
5MG	549	Get Quote
10MG	785	Get Quote
25MG	1122	Get Quote
50MG	1518	Get Quote
100MG	2007	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Palivizumab
Note

Research use only, not for human use.
Brief Description

Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).
Description

Palivizumab (MEDI 493), a humanized respiratory syncytial virus monoclonal antibody, reduces respiratory syncytial virus (RSV) infection.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

JAK/STAT Signaling
Target

STAT
Recptor

RSV
Research Area

——
Indication

——

Chemical Information

CAS Number

188039-54-5
Formula Weight
Molecular Formula

——
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998 Sep;102(3 Pt 1):531-7.?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

Product			Quantity Required*
Name *			E-mail Address *
Organization *			Phone Number
Remarks